DK1165510T3 - 1-arensulfonyl-2-aryl-pyrrolidin- og -piperidinderivater til behandling af CNS-lidelser - Google Patents

1-arensulfonyl-2-aryl-pyrrolidin- og -piperidinderivater til behandling af CNS-lidelser

Info

Publication number
DK1165510T3
DK1165510T3 DK00910863T DK00910863T DK1165510T3 DK 1165510 T3 DK1165510 T3 DK 1165510T3 DK 00910863 T DK00910863 T DK 00910863T DK 00910863 T DK00910863 T DK 00910863T DK 1165510 T3 DK1165510 T3 DK 1165510T3
Authority
DK
Denmark
Prior art keywords
arenesulfonyl
treatment
cns disorders
piperidine derivatives
aryl pyrrolidine
Prior art date
Application number
DK00910863T
Other languages
Danish (da)
English (en)
Inventor
Vincent Mutel
Juergen Wichmann
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1165510T3 publication Critical patent/DK1165510T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK00910863T 1999-03-25 2000-03-18 1-arensulfonyl-2-aryl-pyrrolidin- og -piperidinderivater til behandling af CNS-lidelser DK1165510T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99106004 1999-03-25

Publications (1)

Publication Number Publication Date
DK1165510T3 true DK1165510T3 (da) 2006-02-06

Family

ID=8237852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00910863T DK1165510T3 (da) 1999-03-25 2000-03-18 1-arensulfonyl-2-aryl-pyrrolidin- og -piperidinderivater til behandling af CNS-lidelser

Country Status (34)

Country Link
US (1) US6284785B1 (es)
EP (1) EP1165510B1 (es)
JP (1) JP3590589B2 (es)
KR (1) KR100452648B1 (es)
CN (1) CN1150165C (es)
AR (1) AR028817A1 (es)
AT (1) ATE305451T1 (es)
AU (1) AU765212B2 (es)
BR (1) BR0009278A (es)
CA (1) CA2368418C (es)
CO (1) CO5050296A1 (es)
CZ (1) CZ20013402A3 (es)
DE (1) DE60022867T2 (es)
DK (1) DK1165510T3 (es)
ES (1) ES2249249T3 (es)
HK (1) HK1044944B (es)
HR (1) HRP20010682A2 (es)
HU (1) HUP0200284A3 (es)
IL (1) IL145301A0 (es)
JO (1) JO2274B1 (es)
MA (1) MA26779A1 (es)
MX (1) MXPA01009623A (es)
MY (1) MY125295A (es)
NO (1) NO319948B1 (es)
NZ (1) NZ514037A (es)
PE (1) PE20001583A1 (es)
PL (1) PL204436B1 (es)
RU (1) RU2248350C2 (es)
SI (1) SI1165510T1 (es)
TR (1) TR200102789T2 (es)
TW (1) TW575561B (es)
WO (1) WO2000058285A1 (es)
YU (1) YU67601A (es)
ZA (1) ZA200107689B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US20040267010A1 (en) * 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
US20060035884A1 (en) * 2004-05-20 2006-02-16 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
ES2402362T3 (es) 2004-09-30 2013-05-03 Takeda Pharmaceutical Company Limited Inhibidores de la bomba de protones
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
PE20110009A1 (es) 2005-08-30 2011-01-31 Takeda Pharmaceutical Derivados de pirrol como inhibidores de la secrecion acida
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
US8969387B2 (en) 2008-08-27 2015-03-03 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
US10603313B2 (en) * 2017-07-31 2020-03-31 Chiromics, LLC Allosteric modulators of the mu opioid receptor
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9612884D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
HRP20010682A2 (en) 2002-10-31
DE60022867D1 (de) 2006-02-09
YU67601A (sh) 2004-09-03
DE60022867T2 (de) 2006-06-22
JP3590589B2 (ja) 2004-11-17
TR200102789T2 (tr) 2002-04-22
CA2368418C (en) 2009-03-10
NO20014617L (no) 2001-09-24
AR028817A1 (es) 2003-05-28
NO319948B1 (no) 2005-10-03
ATE305451T1 (de) 2005-10-15
MXPA01009623A (es) 2002-05-06
JP2002540191A (ja) 2002-11-26
PL204436B1 (pl) 2010-01-29
CZ20013402A3 (cs) 2002-03-13
NZ514037A (en) 2004-01-30
TW575561B (en) 2004-02-11
BR0009278A (pt) 2001-12-26
MA26779A1 (fr) 2004-12-20
KR20010108403A (ko) 2001-12-07
MY125295A (en) 2006-07-31
PL350679A1 (en) 2003-01-27
SI1165510T1 (sl) 2005-12-31
AU3291500A (en) 2000-10-16
US6284785B1 (en) 2001-09-04
NO20014617D0 (no) 2001-09-24
ZA200107689B (en) 2002-12-18
HUP0200284A2 (en) 2002-06-29
EP1165510B1 (en) 2005-09-28
KR100452648B1 (ko) 2004-10-12
RU2248350C2 (ru) 2005-03-20
EP1165510A1 (en) 2002-01-02
CO5050296A1 (es) 2001-06-27
WO2000058285A1 (en) 2000-10-05
IL145301A0 (en) 2002-06-30
HUP0200284A3 (en) 2003-04-28
HK1044944A1 (en) 2002-11-08
AU765212B2 (en) 2003-09-11
CN1345311A (zh) 2002-04-17
PE20001583A1 (es) 2001-01-15
CA2368418A1 (en) 2000-10-05
HK1044944B (zh) 2004-10-21
ES2249249T3 (es) 2006-04-01
CN1150165C (zh) 2004-05-19
JO2274B1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
DK1165510T3 (da) 1-arensulfonyl-2-aryl-pyrrolidin- og -piperidinderivater til behandling af CNS-lidelser
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
EE200200442A (et) Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks
AU7394201A (en) Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
DK1468996T3 (da) Indolderivater til behandling af CNS-sygdomme
DK1121356T3 (da) 3-tetrahydropyridin-4-yl-indoler til behandling af psykotiske lidelser
NO20030127D0 (no) Indolderivater nyttige for behandling av CNS-forstyrrelser
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
NO20026029L (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser
DE50003014D1 (de) N-substituierte perhydrodiazine
NO20026028D0 (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
IL153351A0 (en) Indole derivatives useful for the treatment of cns disorders
IL153234A0 (en) Indole derivatives useful for the treatment of cns disorders
SI1305307T1 (en) Indole derivatives useful for the treatment of cns disorders
SI1294710T1 (en) Indole derivatives useful for the treatment of cns disorders